PL3230309T3 - Sposoby wytwarzania długo działających polipeptydów hormonu wzrostu zmodyfikowanych ctp - Google Patents
Sposoby wytwarzania długo działających polipeptydów hormonu wzrostu zmodyfikowanych ctpInfo
- Publication number
- PL3230309T3 PL3230309T3 PL15828386.1T PL15828386T PL3230309T3 PL 3230309 T3 PL3230309 T3 PL 3230309T3 PL 15828386 T PL15828386 T PL 15828386T PL 3230309 T3 PL3230309 T3 PL 3230309T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- growth hormone
- long acting
- producing long
- modified growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
- G06Q10/063—Operations research, analysis or management
- G06Q10/0633—Workflow analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
- G06Q10/063—Operations research, analysis or management
- G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
- G06Q10/063—Operations research, analysis or management
- G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
- G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0201—Market modelling; Market analysis; Collecting market data
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462090116P | 2014-12-10 | 2014-12-10 | |
US201462090124P | 2014-12-10 | 2014-12-10 | |
US201462090104P | 2014-12-10 | 2014-12-10 | |
PCT/IL2015/051196 WO2016092549A1 (en) | 2014-12-10 | 2015-12-10 | Methods of producing long acting ctp-modified growth hormone polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3230309T3 true PL3230309T3 (pl) | 2023-08-28 |
Family
ID=56106835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15828386.1T PL3230309T3 (pl) | 2014-12-10 | 2015-12-10 | Sposoby wytwarzania długo działających polipeptydów hormonu wzrostu zmodyfikowanych ctp |
Country Status (22)
Country | Link |
---|---|
US (3) | US20160168588A1 (pl) |
EP (4) | EP4253407A3 (pl) |
KR (3) | KR102527180B1 (pl) |
CN (1) | CN107438623B (pl) |
AU (2) | AU2015358890B2 (pl) |
CO (1) | CO2017006870A2 (pl) |
EA (1) | EA201791275A1 (pl) |
ES (1) | ES2943359T3 (pl) |
HK (2) | HK1243444A1 (pl) |
HR (1) | HRP20230405T8 (pl) |
IL (2) | IL252778B (pl) |
MX (2) | MX2017007635A (pl) |
NZ (1) | NZ733113A (pl) |
PE (1) | PE20171380A1 (pl) |
PH (1) | PH12017501089A1 (pl) |
PL (1) | PL3230309T3 (pl) |
RU (2) | RU2021103436A (pl) |
SG (1) | SG11201704706RA (pl) |
SI (1) | SI3230309T1 (pl) |
TW (2) | TWI746427B (pl) |
WO (2) | WO2016092550A2 (pl) |
ZA (1) | ZA201704595B (pl) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
EP4253407A3 (en) | 2014-12-10 | 2023-12-06 | OPKO Biologics Ltd. | Methods of producing long acting ctp-modified growth hormone polypeptides |
WO2016203482A2 (en) | 2015-06-19 | 2016-12-22 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
ES2963725T3 (es) * | 2016-07-11 | 2024-04-01 | Opko Biologics Ltd | Factor VII de coagulación de acción prolongada y métodos para producir el mismo |
RU2652884C1 (ru) * | 2016-11-25 | 2018-05-03 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Штамм клеток яичников китайского хомячка сно-еро 4а9 - продуцент высокосиалированного эритропоэтина |
US20200262887A1 (en) * | 2018-11-30 | 2020-08-20 | Opko Ireland Global Holdings, Ltd. | Oxyntomodulin peptide analog formulations |
WO2021005604A1 (en) * | 2019-07-11 | 2021-01-14 | Opko Biologics Ltd. | Long-acting igf-1 or igf-1 variants and methods of producing same |
EP4308151A1 (en) * | 2021-03-19 | 2024-01-24 | Pfizer Inc. | Methods of administering long-acting growth hormone polypeptides |
WO2022197963A1 (en) * | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Long-acting growth hormone compositions |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
ATE110571T1 (de) | 1988-05-06 | 1994-09-15 | Toray Industries | Stabile interferon-beta-zusammensetzung. |
DE69029799T2 (de) | 1989-02-21 | 1997-05-28 | Univ Washington | Modifizierte formen von fortpflanzungshormonen |
DE69011177T2 (de) * | 1989-04-28 | 1994-12-08 | Miles Inc | Grossfermenter-Inokulation mit gefrorenen Zellen. |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
JP4156024B2 (ja) * | 1993-04-20 | 2008-09-24 | ワシントン ユニバーシティー | 修飾されたタンパク質及びペプチド医薬品 |
WO1995035116A1 (en) * | 1994-06-17 | 1995-12-28 | Applied Research Systems | Hgh containing pharmaceutical compositions |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
CN1847265A (zh) * | 2005-04-15 | 2006-10-18 | 上海市计划生育科学研究所 | 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途 |
US9249407B2 (en) * | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8450269B2 (en) * | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US8304386B2 (en) | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) * | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US8759292B2 (en) * | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US20140113860A1 (en) * | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US7553940B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting EPO polypeptides and derivatives thereof and methods thereof |
US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
CN103379949B (zh) * | 2010-10-11 | 2016-09-14 | 艾伯维巴哈马有限公司 | 蛋白纯化方法 |
CA2870621C (en) * | 2012-02-14 | 2022-08-09 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
WO2013152351A2 (en) * | 2012-04-06 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Fusion polypeptides and methods of use thereof |
AU2013250711A1 (en) * | 2012-04-19 | 2014-11-27 | Opko Biologics Ltd. | Long-acting oxyntomodulin variants and methods of producing same |
EP2682168A1 (en) * | 2012-07-02 | 2014-01-08 | Millipore Corporation | Purification of biological molecules |
CN112661863A (zh) * | 2012-11-20 | 2021-04-16 | 奥普科生物制品有限公司 | 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法 |
US11045523B2 (en) * | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
EP4253407A3 (en) | 2014-12-10 | 2023-12-06 | OPKO Biologics Ltd. | Methods of producing long acting ctp-modified growth hormone polypeptides |
WO2016203482A2 (en) * | 2015-06-19 | 2016-12-22 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
-
2015
- 2015-12-10 EP EP23164376.8A patent/EP4253407A3/en active Pending
- 2015-12-10 TW TW104141620A patent/TWI746427B/zh active
- 2015-12-10 EA EA201791275A patent/EA201791275A1/ru unknown
- 2015-12-10 NZ NZ733113A patent/NZ733113A/en unknown
- 2015-12-10 SG SG11201704706RA patent/SG11201704706RA/en unknown
- 2015-12-10 WO PCT/IL2015/051197 patent/WO2016092550A2/en active Application Filing
- 2015-12-10 TW TW110139563A patent/TW202231657A/zh unknown
- 2015-12-10 WO PCT/IL2015/051196 patent/WO2016092549A1/en active Application Filing
- 2015-12-10 US US14/965,079 patent/US20160168588A1/en not_active Abandoned
- 2015-12-10 RU RU2021103436A patent/RU2021103436A/ru unknown
- 2015-12-10 MX MX2017007635A patent/MX2017007635A/es unknown
- 2015-12-10 US US15/533,910 patent/US20180111974A1/en active Pending
- 2015-12-10 KR KR1020227010215A patent/KR102527180B1/ko active IP Right Grant
- 2015-12-10 SI SI201531936T patent/SI3230309T1/sl unknown
- 2015-12-10 KR KR1020207028408A patent/KR20200118505A/ko not_active Application Discontinuation
- 2015-12-10 KR KR1020177018890A patent/KR102164352B1/ko active IP Right Grant
- 2015-12-10 EP EP22209083.9A patent/EP4212546A1/en active Pending
- 2015-12-10 RU RU2017123789A patent/RU2743295C2/ru active
- 2015-12-10 PL PL15828386.1T patent/PL3230309T3/pl unknown
- 2015-12-10 PE PE2017000987A patent/PE20171380A1/es unknown
- 2015-12-10 CN CN201580073554.7A patent/CN107438623B/zh active Active
- 2015-12-10 HR HRP20230405TT patent/HRP20230405T8/hr unknown
- 2015-12-10 EP EP15867141.2A patent/EP3240564A4/en not_active Withdrawn
- 2015-12-10 AU AU2015358890A patent/AU2015358890B2/en active Active
- 2015-12-10 MX MX2017007634A patent/MX2017007634A/es unknown
- 2015-12-10 EP EP15828386.1A patent/EP3230309B1/en active Active
- 2015-12-10 ES ES15828386T patent/ES2943359T3/es active Active
-
2017
- 2017-06-08 IL IL252778A patent/IL252778B/en unknown
- 2017-06-08 IL IL252788A patent/IL252788B/en unknown
- 2017-06-09 PH PH12017501089A patent/PH12017501089A1/en unknown
- 2017-07-07 ZA ZA2017/04595A patent/ZA201704595B/en unknown
- 2017-07-10 CO CONC2017/0006870A patent/CO2017006870A2/es unknown
-
2018
- 2018-03-02 HK HK18103050.1A patent/HK1243444A1/zh unknown
- 2018-05-07 HK HK18105854.4A patent/HK1246322A1/zh unknown
-
2019
- 2019-05-22 AU AU2019203609A patent/AU2019203609B2/en active Active
-
2021
- 2021-02-01 US US17/164,438 patent/US20210371487A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243444A1 (zh) | 長效的ctp修飾的生長激素多肽的製備方法 | |
SG11201608454XA (en) | Methods of controlling nanowire morphology | |
EP3116851A4 (en) | Analogs of fexaramine and methods of making and using | |
RS64053B1 (sr) | Polipeptidi koji reaguju na transformišući faktor rasta – beta i postupci za njihovu upotrebu | |
HK1223283A1 (zh) | 製備注射液的方法 | |
GB2522719B (en) | Method of manufacture | |
HUP1400114A2 (en) | Method for the production of peptides | |
HK1244227A1 (zh) | 長效生長激素劑型 | |
SG11201608761PA (en) | Methods of cellular reprogramming | |
SG11201609173YA (en) | Method of producing nylon | |
IL258981A (en) | Methods for the production of proteins | |
EP3180296A4 (en) | Methods of producing alkylfurans | |
IL252712A0 (en) | Method for protein production | |
SG11201609739UA (en) | Derivatives of dolaproine-dolaisoleuine peptides | |
GB2522716B (en) | Method of manufacture | |
IL249130A0 (en) | Preparation of piperidine-4-carbthioamide | |
HK1232253A1 (zh) | 生產多肽的方法 | |
GB201413590D0 (en) | Method of depositing diamond | |
AU354382S (en) | Lounge setting | |
AU354314S (en) | Lounge setting | |
GB201418283D0 (en) | Production of anti-microbial peptides |